Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (5): 30-34.doi: 10.6040/j.issn.1671-7554.0.2018.223

Previous Articles    

Prognosis related factors of patients with ovarian Sertoli-Leydig cell tumor after fertility-preserving surgery

YANG Ni1, CAO Dongyan1, YANG Jiaxin1, YOU Yan2, SHEN Keng1   

  1. 1. Department of Obstetrics and Gynecology;
    2. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &
    Peking Union Medical College, Beijing 100730, China
  • Received:2018-02-14 Published:2022-09-27

PDF (PC)

21

Abstract: Objective To evaluate the prognosis and its related factors of patients with ovarian Sertoli-Leydig cell tumor(SLCT)after fertility-preserving surgery. Methods Detail clinical data, including survival rates, recurrence, death and fertility states, of 52 SLCT patients after fertility-preserving surgery in Peking Union Medical College Hospital were retrospectively reviewed. Results Forty-one cases showed androgenic manifestations, while 11 cases had no endocrine symptoms. All tumors located in unilaterl ovary; the mean tumor diameter was 10.0 cm(range 2-34 cm); fifty cases were at stage Ⅰ(36 cases at stage ⅠA, 14 cases at stage ⅠC), one was at stage ⅢC, ones stage was unknown; four(7.7%)tumors were well differentiated, 14(26.9%)were intermediately differentiated, 34(65.4%)were poorly differentiated. In the poorly differentiated tumors, 9 had a retiform pattern, 4 had heterologous elements. Six patients(11.5%)underwent cystectomy, 36(69.2%)underwent unilateral salpingo-oophorectomy, and 10(19.2%)underwent standard staging surgery. Twenty-nine patients received systematic chemotherapy(1-4 courses of treatment)after 山 东 大 学 学 报 (医 学 版)56卷5期 -杨旎,等.卵巢支持间质细胞肿瘤保留生育功能治疗的预后及相关因素 \=-the initial surgery. The average follow-up period was 72 months; six cases recurred, in whom 3 cases died. The poor prognosis was correlated with no endocrine symptoms, bigger tumor size, clinical stage >ⅠA, and probably correlated with poor differentiation, retiform pattern and heterologous elements, while not correlated with surgery type and postoperative chemotherapy. Conclusion SLCT is a rare type of sex cord-stromal tumor of the ovary. Most SLCT patients have androgenic manifestations and abdominal masses, and tumors without endocrine changes may indicate more aggressive biological behaviors. The prognosis is correlated with tumor size and clinical stage, and probably correlated with the degree of differentiation. Conservative surgery is acceptable for young patients wishing to preserve fertility, and postoperative adjuvant chemotherapy and long-term follow up are recommended to those with high-risk factors of recurrence.

Key words: Ovarian Sertoli-Leydig cell tumor, Fertility-preserving therapy, Prognosis

CLC Number: 

  • R711.75
[1] Lantzsch T, Stoerer S, Lawrenz K, et al. Sertoli-Leydig cell tumor[J]. Arch Gynecol Obstet, 2001, 264(4): 206-208.
[2] Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases[J]. Am J Surg Pathol, 1985, 9(8): 543-569.
[3] Shu H, Yang X, Gao AF. Ovarian Sertoli-Leydig cell tumor in a 9-month-old infant with special histologic pattern[J]. Fetal Pediatr Pathol, 2012, 31(6): 388-393.
[4] Bhat RA, Lim YK, Chia YN, et al. Sertoli-Leydig cell tumor of the ovary: analysis of a single institution database[J]. J Obstet Gynaecol Res, 2013, 39(1): 305-310.
[5] Weng CS, Chen MY, Wang TY, et al. Sertoli-Leydig cell tumors of the ovary: a Taiwanese Gynecologic Oncology Group study[J]. Taiwan J Obstet Gynecol, 2013, 52(1): 66-70.
[6] Abu-Zaid A, Azzam A, Alghuneim LA, et al. Poorly differentiated ovarian sertoli-leydig cell tumor in a 16-year-old single woman: a case report and literature review[J]. Case Rep Obstet Gynecol, 2013: 858501.
[7] Chang RJ, Dumesic DA. Polycystic ovary syndrome and hyperandrogenic states. In: Yen, Samuel SC, ed. Yen & Jaffes reproductive endocrinology[M]. 5th ed. Philadelphia: Elsevier Saunders, 2004: 597-632.
[8] 肖会廷,李斌,李晓光,等.卵巢支持莱迪细胞瘤15例临床病理分析[J].实用妇产科杂志, 2011, 27(12): 933-936. XIAO Huiting, LI Bin, LI Xiaoguang, et al. Ovarian Sertoli-Leydig cell tumors: clinical pathologic features of 15 cases[J]. J Practical Obstet Gynecol, 2011, 27(12): 933-936.
[9] Chen L, Tunnell CD, De Petris G. Sertoli-Leydig cell tumor with heterologous element: a case report and a review of the literature[J]. Int J Clin Exp Pathol, 2014, 7(3): 1176-1181.
[10] Roth LM, Anderson MC, Govan AD, et al. Sertoli-Leydig cell tumors: a clinicopathologic study of 34 cases[J]. Cancer, 1981, 48(1): 187-197.
[11] Grove A, Vestergaard V. Ovarian Sertoli-Leydig cell tumor of intermediate grade with heterologous elements of rhabdomyosarcoma. A case report and a review of the literature[J]. Ann Diagn Pathol, 2006, 10(5): 288-293.
[12] Liggins CA, Ma LT, Schlumbrecht MP. Sertoli-Leydig cell tumor of the ovary: a diagnostic dilemma[J]. Gynecol Oncol Rep, 2015, 15: 16-19.
[13] Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex-cord stromal tumors of the ovary—an analysis of 376 women[J]. Gynecol Oncol, 2007, 104(2): 396-400.
[14] Schneider DT, Harms D, Calaminus G. Ovarian sex cord stromal tumors in children and adolescents[J]. J Reprod Med, 2005, 50(6): 439-446.
[15] Appetecchia M, Cela V Bernardi F, Burelli A, et al. Sertoli-Leydig cell androgens-estrogens secreting tumor of the ovary: ultra-conservnive surgery[J]. Eur J Obstet Gynecol Reprod Biol, 2004, 116(1): 113-116.
[16] Sahoo TK, Kar T, Kar A, et al. Poorly differentiated Sertoli-Leydig cell tumour of ovary with heterologous elements[J]. J Clin Diagn Res, 2017, 11(5): XD01-XD02.
[17] Sigismondi C, Gadducci A, Lorusso D, et al. Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study[J]. Gynecol Oncol, 2012, 125(3): 673-676.
[18] Litta P, Saccardi C, Conte L, et al. Sertoli-Leydig cell tumors: current status of surgical management: literature review and proposal of treatment[J]. Gynecol Endocrinol, 2013, 29(5): 412-417.
[1] ZHENG Su, CHEN Shuhua, LI Hua, DENG Jie, CHEN Chunhong, WANG Xiaohui, FENG Weixing, HAN Xiaodi, ZHANG Yujia, LI Na, LI Mo, FANG Fang. Correlation between EEG variations and BASED evaluation of the efficacy of ACTH treatment in 54 cases of infantile spasms [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 91-96.
[2] WANG Lihui, GAO Min, KONG Beihua. Angiosarcoma of the uterus: a report of 2 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 108-112.
[3] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[4] ZHANG Yufeng, XU Min, XING Xiuli, PANG Shuguang, HU Keqing. Epidemiological characteristics of 689 patients with non-ST-segment elevation myocardial infarction [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 118-122.
[5] LI Linlin, WANG Kai. Prediction of hepatocellular carcinoma prognostic genes based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 50-58.
[6] CHU Yan, LIU Duanrui, ZHU Wenshuai, FAN Rong, MA Xiaoli, WANG Yunshan, JIA Yanfei. Expressions of DNA methyltransferases in gastric cancer and their clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 1-9.
[7] CHEN Liyu, XIAO Juan, LYU Xianzhong, DUAN Baomin, HONG Fanzhen. Risk factors influencing prognosis of lower extremity deep vein thrombosis in pregnant and parturient women [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 38-42.
[8] TIAN Yaotian, WANG Bao, LI Yeqin, WANG Teng, TIAN Liwen, HAN Bo, WANG Cuiyan. Machine learning models based on interpretive CMR parameters can predict the prognosis of pediatric myocarditis [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 43-49.
[9] LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84.
[10] MI Qi, SHI Shuang, LI Juan, LI Peilong, DU Lutao, WANG Chuanxin. Construction of circRNA-mediated ceRNA network and prognostic assessment model for bladder cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 94-102.
[11] LI Xiangqing, YIN Xin, ZHAO Xuelian, ZHAO Peiqing. Expression and clinical significance of circulating CD56bright subset of NK cells in patients with Parkinsons disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 34-40.
[12] ZENG Rui, HU Xinting, YUN Xiaoya, TIAN Zheng, LI Qing, LIU Jie, ZHANG Ya, WANG Xin. Fluorescence in situ hybridization in the diagnosis of 197 cases of chronic lymphocytic leukemia [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 35-40.
[13] LI Yinglin, SONG Daoqing, XU Zhonghua. Identification of FKBP11 expression in clear cell renal cell carcinoma using bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 45-51.
[14] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47-52.
[15] YAO Yu, WANG Wenjun, LIANG Yuling. Effect of stains on the prognosis of 70 patients with pulmonary embolism [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 76-80.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd